• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

JPMorgan Establishes Life Sciences Private Equity Division

by Fred Pennic 11/02/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.

– The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology.

– The Life Sciences Private Capital team will sit within J.P. Morgan Private Capital, a growth equity and private credit investment platform.

Life Sciences Private Capital Leadership

J.P. Morgan Asset Management has hired industry expert Dr. Stephen Squinto as Chief Investment Officer and Managing Partner of Life Sciences Private Capital. Dr. Squinto joins from OrbiMed Advisors and brings more than 30 years of experience in the biotechnology company building and investing space, having co-founded and built numerous biotechnology companies including Alexion Pharmaceuticals and acting as a key scientific founder of Regeneron Pharmaceuticals.

Joining Dr. Squinto as Co-Managing Partners of the investment strategy are Dr. Gaurav Gupta and Ms. Anya Schiess. Dr. Gupta founded the life science investment firm Ascendant BioCapital and was previously involved in private equity investments at OrbiMed Advisors. Ms. Schiess has over 25 years of experience in healthcare investing and most recently was Co-Founder and General Partner of Healthy Ventures. Full biographies are included below.

“I’m thrilled to join J.P. Morgan to launch the Life Sciences Private Capital team. Our major focus will be to offer our investors a differentiated investment platform that harnesses our deep operational expertise to act as true partners to the companies we invest in – from building strong leadership teams, guiding early drug discovery efforts, designing clinical development programs, and navigating the regulatory environment through to commercial launch strategies,” said Dr. Stephen Squinto, Chief Investment Officer, Life Sciences Private Capital. “As advances in genomics, biomarkers and data science converge, we are seeing firsthand the transformative impact that biomedical innovation can offer to patients at all stages of life and we expect much more to come in the next decade. J.P. Morgan’s existing presence in the healthcare sector will give us a significant sourcing advantage as we seek to identify innovative and transformative therapeutics companies.”

Strategic Advisors

In addition to the hiring of Dr. Squinto, Dr. Gupta and Ms. Schiess, the firm has also attracted a group of Strategic Advisors comprised of some of the life sciences industry’s foremost experts that will help guide the investment strategy, help to source investment opportunities and provide operational expertise to J.P. Morgan’s portfolio companies.  Strategic Advisors include:

– Laurie Glimcher, M.D. – President and CEO, Dana Farber Cancer Institute

– Jeffrey Leiden, M.D., Ph.D. – Executive Chairman, Vertex Pharmaceuticals

– Frederic Moll, M.D. – Chief Development Officer, J&J Medical Devices Companies

– Stephen Oesterle, M.D. – Former Medtronic SVP, Medicine and Technology

– Robert Stockman – Former Chairman, REVA Medical

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Biomarkers, cancer, Drug Discovery, genomics, Life Sciences, Medical Devices, Medtronic, Oncology, OrbiMed, Partners, Private Equity

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |